Related Experiment Video
Updated: Jan 26, 2026

The Combined Use of Transcranial Direct Current Stimulation and Robotic Therapy for the Upper Limb
Published on: September 23, 2018
Combining conventional therapy with immunotherapy: A risky business?
A Coosemans1, A Vankerckhoven2, T Baert3
1Department of Gynaecology and Obstetrics, Leuven Cancer Institute, UZ Leuven, Leuven, Belgium; Department of Oncology, Laboratory of Tumour Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven, Leuven, Belgium.
Combining immunotherapy with chemotherapy lacks preclinical data, potentially leading to devastating patient outcomes. Careful immune monitoring and evidence are crucial before clinical application.
Area of Science:
- Oncology
- Immunology
- Cancer Therapy
Background:
- Immunotherapy is increasingly combined with other treatments due to single-agent failures in various cancers.
- Chemotherapy is the most common combination partner for immunotherapy in clinical trials.
- Limited preclinical data exists for the combination of chemotherapy and immunotherapy.
Purpose of the Study:
- To highlight the critical need for preclinical data and immune monitoring in combined cancer therapies.
- To emphasize the potential risks of combining chemotherapy and immunotherapy without adequate research.
Main Methods:
- Review of existing literature on immunotherapy and chemotherapy combinations.
- Analysis of the complex interactions between cancer cells, immune effector cells, and immunosuppressive cells.
Main Results:
- Significant lack of preclinical evidence supporting chemotherapy-immunotherapy combinations.
- Some studies indicate poor efficacy when combining chemotherapy with immunotherapy.
- Complex interplay between cancer cells and immune cells necessitates thorough investigation.
Conclusions:
- Launching combined therapies without robust preclinical data and immune monitoring poses significant risks.
- Further research is essential to understand the intricate effects of combined chemotherapy and immunotherapy on the tumor microenvironment.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Application of Differentiation to Business
Sign Convention
The normal force acts perpendicular to the beam's cross-section and can...
Enolate Mechanism Conventions
Gene Therapy

